Pliant Therapeutics, Inc. filed 2 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-07-13. Between them they name 4 people, with 1 appointment and 3 departures. Each change below is quoted from the filing and linked to it.
Every change, newest first
Appointed: Robert Iannone
The Board also appointed Dr. Iannone to serve as a member of the Research and Development Committee of the Board (the "R&D Committee") and Dr. Borellini to serve as chairperson of the R&D Committee upon the recommendation of the Nominating and Governance Committee.
Departing: I. Pyott, Chief Executive Officer
(b) Departure of Directors On April 14, 2026, David E.I. Pyott, a Class I director on the Board of Directors (the "Board") of Pliant Therapeutics, Inc. (the "Company") and a member of the Audit Committee and the Nominating and Corporate Governance Committee of the Board, notified the Chief Executive Officer of the Company, Chairman of the Board, and Chair of the Nominating and Corporate Governance Committee of his retirement from the Board and all committees thereof, effective as of the Company's 2026 Annual Meeting of Stockholders (the "Annual Meeting").
Departing: Katharine Knobil, Chief Executive Officer
On April 16, 2026, Katharine Knobil, M.D., a Class II director on the Board and the Chair of the Research and Development Committee and a member of the Nominating and Corporate Governance Committee of the Board, notified the Chief Executive Officer of the Company, Chairman of the Board, and Chair of the Nominating and Corporate Governance Committee of her retirement from the Board and all committees thereof, effective as of the Annual Meeting.
Departing: Suzanne Bruhn, Chief Executive Officer
On April 16, 2026, Suzanne Bruhn, Ph.D., a Class III director on the Board and a member of the Compensation Committee and the Nominating and Corporate Governance Committee of the Board, notified the Chief Executive Officer of the Company, Chairman of the Board, and Chair of the Nominating and Corporate Governance Committee of her intention not to stand for reelection at the Annual Meeting and her retirement from the Board and all committees thereof, effective as of the Annual Meeting.
Find people with the same kind of experience as the Chief Executive Officer at Pliant Therapeutics, Inc., with the record behind each one.
Find candidates like Chief Executive Officer at Pliant Therapeutics, Inc.New leaders review vendors and budgets in their first months. Get an alert the next time Pliant Therapeutics, Inc. is in the news or changes leadership.
Get an alert when Pliant Therapeutics, Inc. changes leadershipTools for this story
Each opens in a new tab, filled in for Pliant Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.